Evidence Grade C — Moderate human evidence. 16 published studies, 11 human. 1 registered clinical trial.
Medically reviewed by a licensed medical professional
TB-500 is a synthetic 7-amino-acid fragment of thymosin beta-4, a naturally occurring protein involved in cell movement and tissue repair. It is often marketed as equivalent to full-length thymosin beta-4, but a 7-amino-acid fragment and a 43-amino-acid protein are pharmacologically distinct molecules. No human clinical trials of TB-500 specifically have been conducted. It is prohibited by WADA.
TB-500 is also known by these brand and alternate names:
16 published studies: 11 human, 3 animal, 5 in-vitro, 5 reviews
TB-500 has no marketing authorisation from any regulatory agency. No human clinical trials of TB-500 specifically have been conducted. The evidence base relies on animal studies of both TB-500 and its parent molecule thymosin beta-4, which are not pharmacologically equivalent.
TB-500 is prohibited by WADA and is known from equine and greyhound racing contexts. Products available through unregulated channels lack pharmaceutical quality assurance. The absence of any human safety or efficacy data means that the compound's effects, risks, interactions, and appropriate dosing in humans are unknown.
TB-500 contains the actin-binding motif (LKKTETQ) from its parent protein thymosin beta-4. Research in animal models and cell culture suggests this fragment may interact with cellular structural proteins. These observations have not been replicated or validated in human studies. The compound is often marketed in grey-market channels as equivalent to full-length thymosin beta-4, but a 7-amino-acid fragment and a 43-amino-acid protein are pharmacologically distinct molecules.
No human clinical trials of TB-500 specifically have been conducted. The evidence base relies on animal studies of both TB-500 and its parent molecule thymosin beta-4, which cannot be assumed to have equivalent effects. TB-500 is known primarily from equine and greyhound racing contexts. A theoretical concern exists around promoting blood vessel growth in tumours (biologically plausible given the mechanism, though not demonstrated). The absence of any human safety, efficacy, interaction, or dosing data means the compound's effects in humans are entirely unknown. Products from unregulated sources lack pharmaceutical quality assurance.
PeptideTrace tracks 1 registered clinical trial for TB-500 sourced from ClinicalTrials.gov.
TB-500 (Thymosin Beta 4 17-23 Fragment) for Cardiovascular Biomarkers in Stable ASCVD
TB-500 is a synthetic 7-amino-acid fragment (LKKTETQ, residues 17-23) of thymosin beta-4 (43 AA, MW 4,963 Da). Fragment MW ~845 Da. Marketed in grey-market as equivalent to full-length Tb4. Not approved by any regulatory agency. Prohibited by WADA. Known from equine/greyhound racing. No established human dosing from trials.
Research suggests activity from actin-binding motif LKKTETQ. Binds G-actin (Kd ~0.5 microM), sequestering from polymerization and modulating dynamics. In animal studies: promotes cell migration, angiogenesis, wound healing via cytoskeletal reorganization. Additional proposed: NF-kappaB modulation, hair follicle stem cell migration, cardiac repair via ILK. Extrapolated from Tb4 research, not validated for fragment in humans.
No marketing authorization. No human trials for TB-500 specifically. Evidence relies on animal studies of both TB-500 and parent Tb4. Tb4 accelerated wound healing in rats (2x closure, Malinda 1999), reduced infarct size in mice (Bock-Marquette, Nature 2004). RegeneRx Phase II trials of full-length Tb4 (RGN-259) for dry eye with mixed results. No fragment-specific clinical data.
The information on this page is provided for educational and research reference purposes only. This is not medical advice. Always consult a qualified healthcare professional before making any health-related decisions.
Compare prices from 71 vendor listings
View pricing data across vendors and countries for TB-500
This entry reflects historical nomenclature for the compound more commonly known as BPC-157. The evidence base, regulatory status, and limitations described for BPC-157 (#81) apply identically to this compound. See compound #81 for the full assessment. No marketing authorisation. No human Phase III trials. No established human dosing or safety profile.
BPC-157 has no marketing authorisation from any major regulatory agency. No human Phase III clinical trials have been completed. The preclinical evidence base consists of over 100 animal studies, predominantly conducted at the University of Zagreb. A small pilot study in ulcerative colitis (4 patients) has been reported but was uncontrolled. No established human dosing, safety profile, or efficacy data from rigorous clinical trials exist. Products available through unregulated channels are not subject to pharmaceutical manufacturing standards, and their composition, purity, and sterility cannot be assured. The gap between the extensive animal literature and the near-complete absence of human clinical data is the defining feature of this compound's evidence base.
Palovarotene (Sohonos) is approved for FOP. The Phase III MOVE trial (107 patients — representing approximately 12% of the global FOP population) initially did not meet statistical significance on its pre-specified primary analysis. However, a post-hoc re-analysis with corrected placebo data showed a 54% reduction in new heterotopic ossification volume. The approval pathway was complex given the ultra-rare nature of FOP. Palovarotene is not a peptide. Important safety considerations include premature growth plate closure in growing children, requiring monitoring. FOP has no other approved treatment.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before making decisions about your health.
